A once-daily pill helped people with type 2 diabetes lose up to 8% of body weight.
Researchers tested the drug orforglipron against oral semaglutide.
Orforglipron lowered blood sugar and reduced appetite without fasting before use.
Participants also achieved better glucose control than with semaglutide.
More than 1,500 adults joined the year-long international study.
Those taking orforglipron lost more weight than patients on semaglutide tablets.
Gastrointestinal side effects caused higher dropout rates with the new drug.
Regulators have not yet approved it.
Experts see major potential for easier, cheaper tablet treatments.
Long-term safety and cardiovascular effects still require further study.
